Shuttle Pharmaceuticals
SHPH
7 hedge funds and large institutions have $210K invested in Shuttle Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
6.22% less ownership
Funds ownership: 13.49% → 7.27% (-6.2%)
42% less capital inflows, than outflows
Capital inflows: $296K | Capital outflows: $509K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ikarian Capital
Dallas,
Texas
|
+$176K |
| 2 |
Boothbay Fund Management
New York
|
+$52.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$30.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connective Capital Management
Palo Alto,
California
|
-$357K |
| 2 |
DRW Securities
Chicago,
Illinois
|
-$152K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$537 |
SHPH Hedge Fund Activity: Q4 2025 in Review
7 of the 8,307 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q4 2025, worth a combined $210K — down 59% from $513K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SHPH positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $176K. The largest seller was Connective Capital Management, exiting entirely with an estimated $357K sold.
- 7 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $210K of Shuttle Pharmaceuticals stock for Q4 2025, down 59% quarter-over-quarter.
- 3 funds opened new Shuttle Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q4 2025 was Ikarian Capital, an estimated $176K added.
- The largest Shuttle Pharmaceuticals seller in Q4 2025 was Connective Capital Management, an estimated $357K sold.
Based on aggregated 13F filings for Q4 2025.